Test tumor markers to predict response after lung cancer chemo
Part of Cancer, Lungs & breathing clinical trials.
This study looks at lab “biomarkers” (measurable clues in patient samples) to see which early-stage lung cancer patients are more likely to benefit after adjuvant chemotherapy. It uses samples from specific earlier clinical trials, so it mainly helps match results to those past treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have early-stage non-small cell lung cancer (NSCLC).
- You must have already had adjuvant chemotherapy after surgery (chemo given to lower relapse risk).
- Your sample must come from one of these past trials: IALT, CALGB-9633, CAN-NCIC-BR10, or ANITA.
- The trial needs the specific archived patient sample(s) from that earlier chemotherapy study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a blood test (ctDNA) can help predict how well a combination of chemotherapy and immunotherapy (and sometimes radiation) works before surgery for non-small cell lung cancer. It aims to see if the blood test can detect small amounts of remaining cancer to guide further treatment.
This study looks for blood markers that can predict how well certain lung cancer treatments work before surgery. By joining, you help find a simple blood test to guide personalized care.
This trial is for people with stage IIA to IIIB non-small cell lung cancer that can be removed by surgery. It tests if certain white blood cells (neutrophils) can help predict how well chemotherapy combined with immunotherapy works before surgery.
This trial tests whether certain markers in your blood or tissue can predict how well immunotherapy works before surgery for early-stage lung cancer. It aims to find out who benefits most from this treatment.
This study looks for early “predictive markers” to tell who is most likely to develop lung inflammation after standard treatment for non-small cell lung cancer. It may help clinicians spot problems sooner and tailor care, using additional monitoring during treatment.
This study looks for blood or tissue markers that can predict who benefits from immunotherapy given before surgery for non-small cell lung cancer. It may help doctors better choose treatment in the future.
Hear when a new Stage IA Non-small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.